Clinical Pharmacology Unit

Simple to complex early phase trial solutions

Our CPU performs the complete spectrum of early exploratory and regulatory clinical studies including, but not limited to: 

• First-in-human (FIH), single ascending dose (SAD)/ multiple ascending dose (MAD) and combined protocols for both new chemical entities and new biological entities 
• Phase 2a proof of concept (PoC) studies  
• Drug/drug interaction (DDI) studies 
• Food effect (FE) studies 
• Bioavailability (BA) and bioequivalence (BE) studies 
• Pharmacokinetic (PK)/pharmacodynamic (PD) studies 
• Studies in special populations (eg postmenopausal women) 
• Age and gender studies 
• PK studies in patient populations.

Studies are performed within our CPU – which has 40 high-monitoring beds and an additional 60 overnight beds – by our highly experienced in-house clinical staff, who always strive to meet the highest quality standards, as proven by our considerable number of successful inspections and audits by international authorities.